Cyrus V. Desouza MBBSProfessor and Chief, of the Division of Diabetes, Endocrinology and Metabolism, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska
Dr. Desouza is a Professor and Chief of the Division of Diabetes, Endocrinology and Metabolism, Department of Internal Medicine at the University of Nebraska Medical Center. He is also the Director of the Diabetes and Obesity Program for the VA Nebraska-Western Iowa Healthcare System (NWIHCS). He is a board-certified clinical endocrinologist with research interests related to cardiovascular disease in insulin resistance and diabetes and improving outcomes in diabetes and obesity.
Dr. Desouza received his medical degree from St. Johns Medical College, Bangalore, India. He completed a rotating internship at St. Johns Medical College, Bangalore, India, senior house officer, internal medicine, Nair Hospital, Topiwala National Medical College, Bombay, India, residency, internal medicine, St. Barnabas Hospital, Bronx, New York, and a fellowship in the Division of Endocrinology, Diabetes and Metabolism at Tulane University, New Orleans, Louisiana.
Dr. Desouza has authored and co-authored several articles in major journals and presents at national and international meetings. He has been a PI for several grants including a VA Merit Review grant looking at glycemic control and other basic cardiovascular related grants. He is a site PI and an ancillary study and steering committee member for a large NIH study: The Glycemic Reduction Approaches for Diabetes: A Comparative Effectiveness Study (GRADE) which is a national study comparing current medications and protocols used in diabetes treatment for an overall assessment of what is more effective. He is also the Chair of the ancillary studies committee in a large NIH trial using Vitamin D to prevent type 2 diabetes (D2d) in people with pre-diabetes. He is involved with a large number of cardiovascular outcomes trials including LEADER, SUSTAIN, PIONEER, Theracos, PROMINENT and serves as a global consultant on some of these trials.
DisclosuresNo disclosures reported.
Recent Contributions to PracticeUpdate:
- SGLT2 Inhibitors Plus GLP-1 Receptor Agonists Yield Benefits Across a Range of CV Outcomes
- All-Cause and CVD Mortality Risk With Early-Onset Diabetes
- Prediabetes and Risk for Cardiovascular Disease by Hypertension Status in Black Adults
- Prediabetes and Risk for Cardiac Death Among Patients With Coronary Artery Disease